Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

lts of operations could be adversely affected. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2008, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.



                            VIROPHARMA INCORPORATED
                        Selected Financial Information


    Consolidated Statements of          Three months         Twelve months
     Operations:                           ended                ended
                                        December 31,          December 31,
    (in thousands, except per           -----------           -----------
     share data)                       2008      2007       2008       2007
                                       ----      ----       ----       ----

    Revenue:
    Net product sales                $50,020   $47,696   $232,307   $203,770
                                      ------    ------    -------    -------
    Revenue                           50,020    47,696    232,307    203,770
                                      ------    ------    -------    -------
    Costs and Expenses:
    Cost of sales (excluding
     amortization of product rights)   2,110     2,034      8,874      8,934
    Research and development          21,197    12,504     66,280     35,869
    Selling, general and
     administrative                   22,357    12,710     65,424     37,051
    Intangible amortization            5,505     1,401     10,809      6,120
    Impairment of fixed assets
     held for sale                     2,265         -      2,265          -
              
'/>"/>
SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... used for detailed studies of what happens on the ... research, among other applications. A group of researchers from ... cell membranes form across a large number of vertical ... the interior of a cell and its surroundings takes ... surface layer that holds the cell together and that ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Trademark Office (PTO) has issued a patent related to ... loss. NB32 is a fixed-dose combination of naltrexone sustained ... No. 8,815,889 claims methods for treating insulin resistance using ... in 2024. If NB32 is approved for use in ...
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... 13 /PRNewswire-Asia/ -- IVT Corporation announced today that,it will demonstrate ... Hong Kong on Nov. 18-19, at Booth F08, and CES ... reducing risk of diseases and,assisting with emergency rescue. , ... It includes: , 1) ...
... Nov. 12 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:,SSRX) ("3SBio" or ... developing, manufacturing and marketing,biopharmaceutical products, today announced its unaudited ... , , Third Quarter 2009 Financial ... by 35.8% over the third quarter of 2008 to, ...
... AvidBiotics Corp. announced the issuance of foundational ... massive diversity within precisely targeted sites of protein-encoding ... to as Diversity Generating Retroelements (DGR) and patents ... and in Europe (#1,173,995). UCLA and AvidBiotics ...
Cached Biology Technology:IVT will Demo Mobile Health System at GSMA Mobile Asia Congress and CES 2010 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 33SBio Inc. Announces Unaudited Third Quarter 2009 Results 43SBio Inc. Announces Unaudited Third Quarter 2009 Results 53SBio Inc. Announces Unaudited Third Quarter 2009 Results 63SBio Inc. Announces Unaudited Third Quarter 2009 Results 73SBio Inc. Announces Unaudited Third Quarter 2009 Results 83SBio Inc. Announces Unaudited Third Quarter 2009 Results 93SBio Inc. Announces Unaudited Third Quarter 2009 Results 103SBio Inc. Announces Unaudited Third Quarter 2009 Results 113SBio Inc. Announces Unaudited Third Quarter 2009 Results 123SBio Inc. Announces Unaudited Third Quarter 2009 Results 133SBio Inc. Announces Unaudited Third Quarter 2009 Results 143SBio Inc. Announces Unaudited Third Quarter 2009 Results 153SBio Inc. Announces Unaudited Third Quarter 2009 Results 163SBio Inc. Announces Unaudited Third Quarter 2009 Results 173SBio Inc. Announces Unaudited Third Quarter 2009 Results 183SBio Inc. Announces Unaudited Third Quarter 2009 Results 193SBio Inc. Announces Unaudited Third Quarter 2009 Results 203SBio Inc. Announces Unaudited Third Quarter 2009 Results 21AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform 2
(Date:9/2/2014)... history of scientific research on mountain ecosystems, looks ... and sets an agenda for biodiversity conservation throughout ... gloom and mountain glory revisited: A survey of ... appears online in the Journal of Mountain ... Tufts University, Jodi A. Hilty of the Wildlife ...
(Date:9/2/2014)... always true that digital distribution of media will ... means, at least when file sizes are large. ... in Yale,s Journal of Industrial Ecology ... for consoles such as PlayStation3. Researchers found that ... greenhouse gas emissions than game files downloaded over ...
(Date:9/2/2014)... R.I. [Brown University] It,s hard to comprehend how ... world has become without knowing what it was before ... pre-human rate was 10 times lower than scientists had ... times worse. , Extinctions are about 1,000 times more ... people came along. The explanation from lead author Jurriaan ...
Breaking Biology News(10 mins):An uphill climb for mountain species? 2An uphill climb for mountain species? 3Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3
... A University of Utah biologist and an international research team ... hope for new ways to attack the major pest, which ... The voracious mites, which technically are not insects, can ... The mites, newly revealed and sequenced genome contains a variety ...
... of Illinois at Chicago College of Medicine describe for ... checkpoint enzymes that must be chemically modified to enable ... thought to play a key role in cancer and ... Nature Structural and Molecular Biology . Telomeres are ...
... recent opening of its new Biomolecular Labeling Laboratory, the ... one of a small handful of facilities in the ... isotopes to make them easier to analyze. The new ... in biomedical fields who also want to take advantage ...
Cached Biology News:Big pest, small genome 2Big pest, small genome 3Big pest, small genome 4UIC study identifies a key molecular switch for telomere extension by telomerase 2Tags? We're it. NIST opens new 'biolabeling' research facility 2
... is a very sensitive immunohistochemical tool for ... both anti-von Willebrand Factor and anti-CD31 primary ... of species. This AP kit provides a ... frozen and paraffin-embedded sections in human (both ...
... Applied Biosystems and MDS Sciex ... System, a high performance hybrid triple ... the drug discovery, drug development or ... (LIT) Technology from the leaders in ...
... 18 amino acid synthetic peptide whose sequence corresponds to residues 1-18 ... (amino to carboxy terminus): M(1) - A - S - A ... S - P - R - D - A - A ... be used for neutralization and control experiments with the polyclonal antibody ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Biology Products: